Assessment of physical and dissolution characteristics of various itraconazole capsule formulations: a comparative analysis


  • Rajan Verma Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Shrikant Hodge Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Chandrashekhar Gargote Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Prakash Modi Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Naresh Upreti Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Lokesh Yadav Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India
  • Raviraj Pillai Innovation and Development, Abbott Healthcare Pvt. Ltd., Mumbai, India



Itraconazole, i-Tyza, BCS class II, Capsule, Pellet, Dissolution profile, Physical characterization


Background: This in vitro study compared physical parameters and the dissolution profile of innovator itraconazole capsule formulation, i-Tyza, and 5 other generic capsule formulations available in the Indian market.

Methods: The number of pellets and size distribution were determined using naked eye examination and sieving method, respectively. Dissolution profile of formulations was done at 15, 30, 45, and 60 minutes, using a United States Pharmacopeia type II Paddle apparatus in simulated gastric fluid (SGF, pH 1.2) without enzymes, acetate buffer (pH 4.5) with 0.5% sodium lauryl sulfate (SLS), and phosphate buffer (pH 6.8) with 0.5% SLS.

Results: All formulations had capsule size 0. Capsule fill weight (~335 to ~510 mg) and total pellet number (127 to 810) varied across formulation, with the innovator brand having the highest number of pellets. Innovator product and i-Tyza had similar fill weight (~460 mg). Pellet size distribution of the innovator product, brand 2, brand 3, and i-Tyza was relatively narrow. In SGF, except brand 1 (84% dissolved) and brand 5 (80% dissolved), all the formulations had near-complete (>85% drug dissolved) or complete dissolution (>90% drug dissolved) at 60 minutes. In acetate buffer, pH 4.5 with 0.5% SLS and phosphate buffer, pH 6.8 with 0.5% SLS, only the innovator product and i-Tyza demonstrated near-complete to complete dissolution at 60 minutes (96% and 90% dissolved).

Conclusions: Across all the itraconazole generic formulations evaluated, i-Tyza had comparable physical characteristics and dissolution profile to the innovator product. The in vitro dissolution profile of i-Tyza may indicate adequate in vivo performance.


Clemons KV, Richardson MD. Chapter 7-Pathways and routes of natural exposure to fungal infection. In: Viegas C, Pinheiro AC, Sabino R, Viegas S, Brandão J, Veríssimo C, eds. Environmental Mycology in Public Health Fungi and Mycotoxins Risk Assessment and Management. Academic Press; 2016: 65-76.

Bitew A. Dermatophytosis: prevalence of dermatophytes and non-dermatophyte fungi from patients attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia. Dermatol Res Pract. 2018:8164757.

Avancini J, Zucchi P. Prevalence of dermatoses in patients referred for evaluation in an outpatient clinic of specialties. An Bras Dermatol. 2018;93:513-6.

Fallahi AA, Rezaei-Matehkolaei A, Rezaei S. Epidemiological status of dermatophytosis in Guilan, north of Iran. Curr Med Mycol. 2017;3:20-4.

Ismail MT, Al-Kafri A. Epidemiological survey of dermatophytosis in Damascus, Syria, from 2008 to 2016. Curr Med Mycol. 2016;2:32-6.

Nweze EI, Eke IE. Dermatophytes and dermatophytosis in the eastern and southern parts of Africa. Med Mycol. 2018;56:13-28.

Patwardhan N, Dave R. Dermatomycosis in and around Aurangabad. Indian J Pathol Microbiol. 1999;42:455-62.

Lakshmanan A, Ganeshkumar P, Mohan SR, Hemamalini M, Madhavan R. Epidemiological and clinical pattern of dermatomycoses in rural India. Indian J Med Microbiol. 2015;33S:134-6.

Tripathy S. Rising prevalence of dermatophytosis in India: a matter of concern. Int J Infect Dis. 2016;45:318.

Sudha M, Ramani CP, Anandan H. Prevalence of dermatophytosis in patients in a tertiary care centre. Int J Contemporary Med Res. 2016;3:2399-401.

Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18:6.

Odds FC, Oris M, Van Dorsselaer P, Van Gerven F. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agent Chemother. 2000;44:3180-3.

Heykants J, Michiels M, Meuldermans W, Monabaliu J, Lavrisjen K, Van Peer A, et al. The pharmacokinetics of itraconazole in animals and man: an overview. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Prous Science Publishers; 1989: 223-49.

Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(S1):67-87.

Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585-620.

Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub therapeutic levels and resistance. Int J Antimicrob Agents. 2007;30:93-4.

Franchimont PG, De Doncker P, Van de Velde V, Jacqmin P, Arrese JE, Pierard GE. Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann Soc Belg Med Trop. 1995;75:211-7.

Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91:1414-22.

Shargel L, Andrew BC, Wu-Pong S. Applied biopharmaceutics and pharmacokinetics. Stamford: Appleton and Lange; 1999.

Ramesh V, Meenakshi S, Jyothirmayee N, Bullebbai M, Noorjahan SK, Rajeswar G. Enhancement of solubility, dissolution rate and bioavailability of BCS class II drugs. Int J Pharma Chem Res. 2016;2:80-95.

Baert LEC, Verreck G, Thone D. Antifungal compositions with improved bioavailability. US Patent; 2003: US 6,509,038 B2.

Sirisha KVR, Sri KV, Suresh K, Reddy GK. Devanna N. A review of pellets and pelletization process-a multiparticulate drug delivery system. Int J Pharm Sci Res. 2013;4:2145-58.

Uppoor VR. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release. 2001;72:127-32.

Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). United States Food and Drug Administration; 1997.

Singla N, Gupta GD, Kohli K, Singla AK. A discriminatory and biorelevant dissolution test method for simvastatin drug products. Dissolution Technol. 2009;16:11-3.

Taupitz T, Klein S. Can biorelevant media be simplified by using SLS and tween 80 to replace bile compounds. Open Drug Deliv J. 2010;4:30-7.

Sardana K, Khurana A, Singh A, Gautam RK. A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018;9:426-31.

Kapoor BS, Subbaro GV. Formulation development and characterization of itraconazole granules. Int J Pharm Sci Nanotechnol. 2011;4:1497-500.

Swaminathan S, Sangwai M, Wawdhane S, Vavia P. Soluble itraconazole in tablet form using disordered drug delivery approach: Critical scale-up considerations and bio equivalence studies. AAPS Pharm Sci Tech. 2013;14:360-74.






Original Research Articles